MARKET

NKGN

NKGN

NKGen Biotech Inc
OTCPK
0.151
-0.005
-3.20%
Closed 13:54 03/26 EDT
OPEN
0.171
PREV CLOSE
0.156
HIGH
0.177
LOW
0.151
VOLUME
59.56K
TURNOVER
9.62K
52 WEEK HIGH
2.570
52 WEEK LOW
0.120
MARKET CAP
6.80M
P/E (TTM)
-0.0732
1D
5D
1M
3M
1Y
5Y
1D
NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)
Barchart · 1d ago
Weekly Report: what happened at NKGN last week (0317-0321)?
Weekly Report · 2d ago
Weekly Report: what happened at NKGN last week (0310-0314)?
Weekly Report · 03/17 11:10
Weekly Report: what happened at NKGN last week (0303-0307)?
Weekly Report · 03/10 11:12
NKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock split
TipRanks · 03/04 18:11
NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented
Barchart · 03/04 12:00
NKGen Biotech announces administration of first dose of troculeucel
TipRanks · 03/03 13:11
NKGEN BIOTECH ANNOUNCES ADMINISTRATION OF FIRST DOSE OF TROCULEUCEL TO STROKE PATIENT UNDER FDA-CLEARED COMPASSIONATE USE PROGRAM
Reuters · 03/03 13:00
More
About NKGN
NKGen Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapeutics. Its product candidates are based on a manufacturing and cryopreservation process, which produces SuperNK (SNK) cells. SNK cells can be produced in large quantities and cryopreserved, while maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. It is developing SNK01, an autologous natural killer (NK) cell therapy, for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its autologous NK cell therapy candidate has clinical trials in several therapeutic areas, including oncology and neurodegeneration. SNK02 is its allogeneic NK cell product candidate. It is conducting clinical trials with its SNK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).

Webull offers NKGen Biotech Inc stock information, including OTCPK: NKGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKGN stock methods without spending real money on the virtual paper trading platform.